Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart's 1000 mg dose, administered through a subcutaneous ...

The LifeSite Hemodialysis Access System was designed as a totally subcutaneous alternative to hemodialysis catheters. It combines port and catheter technology, allowing immediate use on implantation.